Freeline Therapeutics Limited announced that Jan Thirkettle, former VP, Cell & Gene Therapy Platform at GSK, has been appointed Chief Development Officer and Gerard Short, former Senior Medical Director at Genzyme Corporation, has been appointed VP, Head of Clinical and Regulatory. Dr. Jan Thirkettle joins Freeline from GSK where he was VP, Cell & Gene Therapy Platform. In this capacity, over the period of 4 years, he built GSK's Chemistry, Manufacturing and Control (CMC)/supply capabilities in the cell & gene therapy field, enabling the submission of a Marketing Authorisation Application (MAA) for an ex vivo gene therapy for ADA-SCID in 2015 and establishment of a portfolio of technologies and programmes.

Dr. Gerard Short joins Freeline from Genzyme Corporation where he was the global clinical development lead for Genzyme's Pompe's Disease programme, including Myozyme/Lumizyme and the second generation enzyme replacement therapy, NeoGAA.